[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Luciano A. Sposato\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100562660","wso-beat-stroke-initiative-100562660",false,"NCT06606054","WSO BEAT STROKE Initiative","WSO - The Brain and hEart globAl iniTiative (BEAT) Stroke","BEAT STROKE","Inclusion Criteria:\n\n* Patients with ischemic stroke or TIA of any etiology.\n\nExclusion Criteria:\n\n* N\u002FA","ALL","18 Years",{"count":20,"type":21},2400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The WSO Brain and hEart globAl iniTiative - STROKE (BEAT-STROKE) is a cluster randomized controlled trial, testing whether an educational and implementation Neurocardiology tool can improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1",[27,28,29],"Stroke","PFO - Patent Foramen Ovale","Atrial Fibrillation (AF)",[31,32,33,34],"cardiac monitoring","stroke","atrial fibrillation","pfo closure","NOT_YET_RECRUITING","2026-09-15",{"date":38,"type":39},"2026-09-18","ACTUAL",{"date":41,"type":21},"2027-03",{"date":43,"type":21},"2029-12",{"name":45,"class":46},"Luciano A. Sposato","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100494164","mr-evidence-of-cardiac-inflammation-post-stroke-100494164","NCT05714618","MR Evidence of Cardiac Inflammation Post-Stroke","Magnetic Resonance Imaging Evidence of Cardiac Inflammation Post-Stroke","MIRACLE","Inclusion Criteria:\n\n• Acute ischemic stroke in the right or left MCA territory. Acute ischemic stroke is defined as acute onset focal symptoms matching an acute brain infarct documented on Head computed tomography or diffusion-weighted imaging (DWI) MRI of the brain showing restricted diffusion.\n\nExclusion Criteria:\n\n* History of known atrial fibrillation, prior myocardial infarction, coronary artery disease, heart failure, prior cardiovascular surgery or percutaneous intervention.\n* Previous stroke (occurred within 3 months before the index event)\n* Impaired renal function defined as a creatinine clearance \\\u003C97 mL\u002Fmin in men or \\\u003C88 mL\u002Fmin in women, according to the Cockcroft formula.\n* hs-TnT \\>100 on routine acute stroke baseline bloodwork upon admission.\n* Clinically or neurologically unstable patients as per the treating physician.\n* Ongoing infection or recent infection within the previous 3 months\n* Surgery within 3 months before the stroke\n* Concurrent and active inflammatory conditions (connective tissue diseases, rheumatological disease, etc.) or use of anti-inflammatory medications\n* Pregnancy, Stage IV renal insufficiency, eGFR \\\u003C30, and any other contraindications to the use of gadolinium.\n* Stroke with symptomatic hemorrhagic transformation\n* Subjects will be excluded if they fail the LHSC standard MRI screening questionnaire (cardiac pacemakers\u002Fwires, aneurysm clips, shunt\u002Fsurgical clips, shrapnel\u002Fbullets, dentures or metal braces, intra-uterine devices, heart valves, ear implants, prostheses, medication patches such as Nicoderm, Habitrol, or Transderm-Nitro, claustrophobia, history of a head or eye injury involving metal fragments.",{"count":57,"type":21},44,"OBSERVATIONAL","The present study is an investigator initiated, single-centre, prospective, proof-of-concept cohort study aiming to enroll 44 patients with acute middle cerebral artery (MCA) ischemic stroke, involving the right (n=22) and left (n=22) MCA territories and 24 control patients with acute focal neurological symptoms but no evidence of acute brain infarct on DWI-MRI.",[61,62,63],"Stroke, Ischemic","Inflammation","Myocardial Injury","RECRUITING",{"date":38,"type":39},{"date":67,"type":39},"2021-10-01",{"date":69,"type":21},"2027-12-31",{"name":45,"class":46},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":47},"100561402","b2ad-risk-afdas-evolution-of-burden-of-af-100561402","NCT06589700","B2AD-Risk AFDAS Evolution of Burden of AF","Evolution of Burden of AF Biomarkers, Left Atrial Characteristics, Demographics,and Risk Factors in AF Detected After Stroke","B2AD-Risk AF","Inclusion Criteria:\n\n* Adult patients with cortical or subcortical, cryptogenic or non-cryptogenic acute ischemic stroke\n* Any of the following types of AF:\n* Paroxysmal AF known before stroke onset (KAF).\n* Paroxysmal AF found on an admission or Emergency Department ECG (ECG-AFDAS)\n* Paroxysmal AF found on 14-day Holter monitoring (PCM-AFDAS)\n\nExclusion Criteria:\n\n* Patients not willing to consent\n* Permanent or persistent AF\n* Allergy to iodinated contrast agents",{"count":80,"type":21},24,[24],"Each year, 7.8 million people worldwide experience an ischemic stroke, often caused by atrial fibrillation (AF). AF is a major contributor to severe, disabling, and deadly strokes. About 20% to 30% of ischemic stroke patients have AF before their stroke. Of the remaining 70% to 80% without known arrhythmias, up to 24% are newly diagnosed with AF after intensive cardiac monitoring, totaling 1.3 to 1.5 million new AF cases detected after stroke globally each year. Oral anticoagulants (OACs) can reduce stroke risk related to AF by 64% and lead to milder strokes with lower disability and mortality. Neurologists use cardiac monitoring to detect AF in stroke patients.\n\nThis study focuses on patients who have had an ischemic stroke and are newly diagnosed with AF. The goal is to understand how AF progresses over time. The investigators will track changes in AF severity and frequency, monitor biomarkers related to heart health, assess the size and function of the left atrium, and observe new risk factors like hypertension. Patients will be grouped based on their AF diagnosis method: ECG, a portable device recording heart activity for less than 7 days, or one recording for 7 to 30 days.\n\nThe investigators hypothesize that AF burden will increase, new risk factors will emerge, biomarkers will rise, and the left atrium will worsen over time. Participants will be followed for up to 24 months with regular assessments. The study aims to provide insights into AF progression in stroke patients, potentially improving treatments and prevention strategies.",[27,84],"Atrial Fibrillation",[86,32,87],"Implantable Loop Recorder","Atrial fibrillation","2026-05-03",{"date":90,"type":39},"2026-05-07",{"date":92,"type":39},"2025-10-16",{"date":94,"type":21},"2027-10",{"name":45,"class":46},""]